Table 2.

Mean adjusted per-month per-patient cost differential associated with PP utilization over 12 months post-index

Cost parameter	Estimate	Wald 95 % confidence limits		ProbChiSq
		Lower	Upper
All-cause costs
Inpatient costs	−234.19	−361.70	−106.67	0.0003
Emergency department costs	−5.14	−11.64	1.35	0.1208
Outpatient costs	−335.89	−382.11	−289.67	<0.0001
Outpatient office visit costs	−0.55	−2.13	1.02	0.4922
Other outpatient costs	−330.19	−375.29	−285.09	<0.0001
Pharmacy costs	1003.65	986.21	1021.09	<0.0001
Total costsa	433.58	297.88	569.27	<0.0001
Mental-health-related costsb
Inpatient costs	−270.56	−354.67	−186.45	<0.0001
Emergency department costs	−0.22	−2.79	2.35	0.8658
Outpatient costs	−285.94	−317.70	−254.17	<0.0001
Outpatient office visit costs	2.81	2.10	3.52	<0.0001
Other outpatient costs	−288.52	−320.12	−256.93	<0.0001
Pharmacy costs	1019.30	1004.50	1034.10	<0.0001
Total costsa	462.80	373.95	551.65	<0.0001

Values are in 2012 US dollars

Reflects the mean monthly cost differential for patient months with PP compared to without PP, adjusted for the covariates shown in Table 1

PP paliperidone palmitate

^aComponents do not sum to total costs because each cost parameter was modeled separately

^bIncludes claims with a primary diagnosis of ICD-9 290.xx–319.xx and pharmacy claims for all classes of psychiatric medications